Evans Josie M M, Ogston Simon A, Reimann Frank, Gribble Fiona M, Morris Andrew D, Pearson Ewan R
Diabetes Obes Metab. 2008 Apr;10(4):350-2. doi: 10.1111/j.1463-1326.2007.00833.x. Epub 2007 Dec 17.
To assess whether users of pancreatic-specific sulphonylureas are at reduced risk of mortality and cardiovascular mortality compared with users of non-specific sulphonylureas, we conducted a cohort study in the population of Tayside, Scotland. We identified 3331 patients with type 2 diabetes who were newly treated with sulphonylureas between 1994 and 2001 and categorized them into those treated with only pancreatic-specific sulphonylureas and those treated with only non-specific sulphonylureas. The risks of mortality and cardiovascular mortality were compared in a survival analysis. There were 2914 patients treated with pancreatic-specific sulphonylureas only, of which 683 (23.4%) died. Of 186 patients treated with non-specific drugs only, 40 (21.5%) died. After adjusting for confounding factors, the adjusted risk ratios (with 95% CI) for mortality and cardiovascular mortality were 0.84 (0.61 to 1.17) and 0.81 (0.59 to 1.11) among the non-specific users compared with the pancreatic-specific users. This provides no evidence that there are differences between the two sulphonylureas types.
为评估与非特异性磺脲类药物使用者相比，胰腺特异性磺脲类药物使用者的死亡风险和心血管疾病死亡风险是否降低，我们在苏格兰泰赛德地区人群中开展了一项队列研究。我们确定了3331例于1994年至2001年间开始接受磺脲类药物新治疗的2型糖尿病患者，并将他们分为仅接受胰腺特异性磺脲类药物治疗的患者和仅接受非特异性磺脲类药物治疗的患者。在生存分析中比较了死亡风险和心血管疾病死亡风险。仅接受胰腺特异性磺脲类药物治疗的患者有2914例，其中683例（23.4%）死亡。仅接受非特异性药物治疗的186例患者中，40例（21.5%）死亡。在对混杂因素进行校正后，与胰腺特异性药物使用者相比，非特异性药物使用者的死亡和心血管疾病死亡的校正风险比（及95%置信区间）分别为0.84（0.61至1.17）和0.81（0.59至1.11）。这没有提供证据表明两种磺脲类药物之间存在差异。
